Literature DB >> 10200308

Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors.

J M Polo1, B A Belli, D A Driver, I Frolov, S Sherrill, M J Hariharan, K Townsend, S Perri, S J Mento, D J Jolly, S M Chang, S Schlesinger, T W Dubensky.   

Abstract

Alphavirus vectors are being developed for possible human vaccine and gene therapy applications. We have sought to advance this field by devising DNA-based vectors and approaches for the production of recombinant vector particles. In this work, we generated a panel of alphavirus vector packaging cell lines (PCLs). These cell lines were stably transformed with expression cassettes that constitutively produced RNA transcripts encoding the Sindbis virus structural proteins under the regulation of their native subgenomic RNA promoter. As such, translation of the structural proteins was highly inducible and was detected only after synthesis of an authentic subgenomic mRNA by the vector-encoded replicase proteins. Efficient production of biologically active vector particles occurred after introduction of Sindbis virus vectors into the PCLs. In one configuration, the capsid and envelope glycoproteins were separated into distinct cassettes, resulting in vector packaging levels of 10(7) infectious units/ml, but reducing the generation of contaminating replication-competent virus below the limit of detection. Vector particle seed stocks could be amplified after low multiplicity of infection of PCLs, again without generating replication-competent virus, suggesting utility for production of large-scale vector preparations. Furthermore, both Sindbis virus-based and Semliki Forest virus-based vectors could be packaged with similar efficiency, indicating the possibility of developing a single PCL for use with multiple alphavirus-derived vectors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10200308      PMCID: PMC16378          DOI: 10.1073/pnas.96.8.4598

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  DNA vaccines with a kick.

Authors:  J M Polo; T W Dubensky
Journal:  Nat Biotechnol       Date:  1998-06       Impact factor: 54.908

2.  Establishment and maintenance of persistent infection by Sindbis virus in BHK cells.

Authors:  B Weiss; R Rosenthal; S Schlesinger
Journal:  J Virol       Date:  1980-01       Impact factor: 5.103

3.  Multiple structurally related defective-interfering RNAs formed during undiluted passages of Semliki forest virus.

Authors:  L Kääriäinen; R F Pettersson; S Keränen; P Lehtovaara; H Söderlund; P Ukkonen
Journal:  Virology       Date:  1981-09       Impact factor: 3.616

4.  Simian virus 40 early mRNA's. I. Genomic localization of 3' and 5' termini and two major splices in mRNA from transformed and lytically infected cells.

Authors:  V B Reddy; P K Ghosh; P Lebowitz; M Piatak; S M Weissman
Journal:  J Virol       Date:  1979-04       Impact factor: 5.103

5.  Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.

Authors:  P Pushko; M Parker; G V Ludwig; N L Davis; R E Johnston; J F Smith
Journal:  Virology       Date:  1997-12-22       Impact factor: 3.616

6.  Enhancing immune responses using suicidal DNA vaccines.

Authors:  P Berglund; C Smerdou; M N Fleeton; I Tubulekas; P Liljeström
Journal:  Nat Biotechnol       Date:  1998-06       Impact factor: 54.908

7.  Common and distinct regions of defective-interfering RNAs of Sindbis virus.

Authors:  S S Monroe; S Schlesinger
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

8.  Infection of neuroblastoma cells by Semliki Forest virus. The interference of viral capsid protein with the binding of host messenger RNAs into initiation complexes is the cause of the shut-off of host protein synthesis.

Authors:  H van Steeg; M Kasperaitis; H O Voorma; R Benne
Journal:  Eur J Biochem       Date:  1984-02-01

9.  Construction of a helper cell line for avian reticuloendotheliosis virus cloning vectors.

Authors:  S Watanabe; H M Temin
Journal:  Mol Cell Biol       Date:  1983-12       Impact factor: 4.272

10.  RNAs from two independently isolated defective interfering particles of Sindbis virus contain a cellular tRNA sequence at their 5' ends.

Authors:  S S Monroe; S Schlesinger
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

View more
  44 in total

1.  Development of a rubella virus vaccine expression vector: use of a picornavirus internal ribosome entry site increases stability of expression.

Authors:  K V Pugachev; W P Tzeng; T K Frey
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 2.  Vectors for gene therapy of cardiovascular disease.

Authors:  J F Dedieu; A Mahfoudi; A Le Roux; D Branellec
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

3.  Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein.

Authors:  J P Gardner; I Frolov; S Perri; Y Ji; M L MacKichan; J zur Megede; M Chen; B A Belli; D A Driver; S Sherrill; C E Greer; G R Otten; S W Barnett; M A Liu; T W Dubensky; J M Polo
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Incorporation of tick-borne encephalitis virus replicons into virus-like particles by a packaging cell line.

Authors:  Rainer Gehrke; Michael Ecker; Stephan W Aberle; Steven L Allison; Franz X Heinz; Christian W Mandl
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

5.  Structural evidence of glycoprotein assembly in cellular membrane compartments prior to Alphavirus budding.

Authors:  Pan Soonsawad; Li Xing; Emerson Milla; Juan M Espinoza; Masaaki Kawano; Michael Marko; Chyongere Hsieh; Hiromitsu Furukawa; Masahiro Kawasaki; Wattana Weerachatyanukul; Ranjana Srivastava; Susan W Barnett; Indresh K Srivastava; R Holland Cheng
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

6.  In vitro and in vivo characterization of microRNA-targeted alphavirus replicon and helper RNAs.

Authors:  Kurt I Kamrud; V McNeil Coffield; Gary Owens; Christin Goodman; Kim Alterson; Max Custer; Michael A Murphy; Whitney Lewis; Sarah Timberlake; Elizabeth K Wansley; Peter Berglund; Jonathan Smith
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

7.  Vaccines timeline. Interview by Philip Cohen.

Authors:  M A Liu
Journal:  BMJ       Date:  1999-11-13

8.  Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles.

Authors:  N L Davis; I J Caley; K W Brown; M R Betts; D M Irlbeck; K M McGrath; M J Connell; D C Montefiori; J A Frelinger; R Swanstrom; P R Johnson; R E Johnston
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

9.  Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.

Authors:  Soumi Gupta; Ramesh Janani; Qian Bin; Paul Luciw; Catherine Greer; Silvia Perri; Harold Legg; John Donnelly; Susan Barnett; Derek O'Hagan; John M Polo; Michael Vajdy
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

10.  An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.

Authors:  Silvia Perri; Catherine E Greer; Kent Thudium; Barbara Doe; Harold Legg; Hong Liu; Raul E Romero; Zequn Tang; Qian Bin; Thomas W Dubensky; Michael Vajdy; Gillis R Otten; John M Polo
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.